Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status
Authors
Keywords
-
Journal
Journal of Clinical Medicine
Volume 9, Issue 4, Pages 940
Publisher
MDPI AG
Online
2020-04-03
DOI
10.3390/jcm9040940
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Rucaparib: A Review in Ovarian Cancer
- (2019) Matt Shirley Targeted Oncology
- PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers
- (2019) Man Keung et al. Journal of Clinical Medicine
- Novel insights into PARPs in gene expression: regulation of RNA metabolism
- (2019) Yueshuang Ke et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Evidence to date: talazoparib in the treatment of breast cancer
- (2019) Pedro Exman et al. OncoTargets and Therapy
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
- (2018) Jennifer K. Litton et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association Between BRCA Status and Triple-Negative Breast Cancer: A Meta-Analysis
- (2018) Haixia Chen et al. Frontiers in Pharmacology
- PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow
- (2018) Todd A. Hopkins et al. MOLECULAR CANCER RESEARCH
- Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response–Targeted Therapies in Breast Cancer
- (2017) Kalnisha Naidoo et al. MOLECULAR CANCER THERAPEUTICS
- HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
- (2017) Helen Davies et al. NATURE MEDICINE
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer
- (2016) Benjamin H. Lok et al. CLINICAL CANCER RESEARCH
- Proteogenomics connects somatic mutations to signalling in breast cancer
- (2016) Philipp Mertins et al. NATURE
- Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
- (2016) Y. Pommier et al. Science Translational Medicine
- Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in Human Breast Cancer Cells
- (2015) Józefa Węsierska-Gądek et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors
- (2015) T. A. Hopkins et al. MOLECULAR CANCER RESEARCH
- The Global Burden of Cancer 2013
- (2015) Christina Fitzmaurice et al. JAMA Oncology
- Ovarian Cancer-associated Mutations Disable Catalytic Activity of CDK12, a Kinase That Promotes Homologous Recombination Repair and Resistance to Cisplatin and Poly(ADP-ribose) Polymerase Inhibitors
- (2014) Poorval M. Joshi et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity
- (2013) I. Bajrami et al. CANCER RESEARCH
- Review of Poly (ADP-ribose) Polymerase (PARP) Mechanisms of Action and Rationale for Targeting in Cancer and Other Diseases
- (2013) Julio Morales et al. CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION
- Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
- (2013) J. Murai et al. MOLECULAR CANCER THERAPEUTICS
- Triple Negative Breast Tumors in African-American and Hispanic/Latina Women Are High in CD44+, Low in CD24+, and Have Loss of PTEN
- (2013) Yanyuan Wu et al. PLoS One
- Identification of Pim Kinases as Novel Targets for PJ34 with Confounding Effects in PARP Biology
- (2012) Albert A. Antolín et al. ACS Chemical Biology
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 Inactivation
- (2012) T. Popova et al. CANCER RESEARCH
- The clonal and mutational evolution spectrum of primary triple-negative breast cancers
- (2012) Sohrab P. Shah et al. NATURE
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- Structural Basis for DNA Damage-Dependent Poly(ADP-ribosyl)ation by Human PARP-1
- (2012) M.-F. Langelier et al. SCIENCE
- Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents
- (2012) Nicolai J. Birkbak et al. Cancer Discovery
- The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes
- (2011) D. Blazek et al. GENES & DEVELOPMENT
- Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2
- (2010) Nancie Petrucelli et al. GENETICS IN MEDICINE
- Histological types of breast cancer: How special are they?
- (2010) Britta Weigelt et al. Molecular Oncology
- Resistance to Trastuzumab in Breast Cancer
- (2009) P. R. Pohlmann et al. CLINICAL CANCER RESEARCH
- Transcriptional control by PARP-1: chromatin modulation, enhancer-binding, coregulation, and insulation
- (2008) W Lee Kraus CURRENT OPINION IN CELL BIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started